OA
TECX

Omega Advisors’s Tectonic Therapeutic TECX Stock Holding History

Omega Advisors’s Portfolio TECX Stock Details TECX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,167
Closed -$1.43M – 72
2018
Q2 		$1.43M Buy
+4,167
New +$1.5M 0.05% 73

Other funds holding TECX

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Omega Advisors's TECX Position: Q3 2018 in Review

Omega Advisors sold out of Tectonic Therapeutic (TECX) in Q3 2018, closing a stake of 4,167 shares — an estimated $1.43M sold.

Omega Advisors first reported a position in TECX in Q2 2018 and held it in 1 quarter. The position peaked at $1.43M in Q2 2018. 63 funds tracked by Wall St. Rank hold TECX as of Q3 2018.

  • Omega Advisors reported no remaining Tectonic Therapeutic position as of Q3 2018 after selling out during the quarter.
  • Omega Advisors sold 4,167 Tectonic Therapeutic shares in Q3 2018, an estimated $1.43M.
  • Omega Advisors first reported a position in Tectonic Therapeutic in Q2 2018 and held it in 1 quarter.
  • Omega Advisors's Tectonic Therapeutic position peaked at $1.43M in Q2 2018.
  • 63 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q3 2018.

Based on Omega Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.